05:44 PM EST, 12/09/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer.

The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical control at The University of Texas MD Anderson Cancer Center.

The treatment was well-tolerated, and investigators concluded that its favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial, the company said.

Following positive results, MD Anderson received US FDA clearance for an additional cohort studying NBTXR3 with chemoradiation. Recruitment for the new cohort is ongoing.

Nanobiotix ( NBTX ) anticipates that MD Anderson will present full results from the completed study phases at a medical congress in H1 2025.